<DOC>
	<DOCNO>NCT00690833</DOCNO>
	<brief_summary>The purpose research study well understand study drug work people use treat atopic dermatitis . Desonate approve US Food Drug Administration ( FDA ) atopic dermatitis .</brief_summary>
	<brief_title>Efficacy Desonide ( Desonatetm ) Gel 0.05 % Younger Older Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>To assess efficacy desonide hydrogel 0.05 % young child ( age &lt; 13 ) old subject ( age 13 ) mild moderate atopic dermatitis</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Desonide</mesh_term>
	<criteria>Male female , age 3 month great . Subjects must diagnosis mild moderate atopic dermatitis investigator ( 2 3 IGA scale ) . Subjects must &gt; 2 % BSA involvement enrol . Informed consent participation must give parent guardian &lt; 7 year old . Children 7 18 year old give assent form sign . Moisturizers allow study long use remain stable screening/baseline throughout study . Known allergy sensitivity topical desonide hydrogel subject . Inability complete studyrelated visit . Introduction prescription medication , topical systemic , atopic dermatitis participate study . Other stable use counter nonmedicated moisturizers , topical treatment AD must stop prior study drug initiation . There require washout topical therapy . Stable use systemic therapy may continue throughout study . Requiring &gt; 130 gm cream 4 week period . Pregnant woman woman breastfeed exclude . Women childbearing potential allow participate study , subject require use least one form birth control . Use desonide pregnant subject controversial use benefit outweigh risk .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>